Alergologie Nemcova s.r.o.
- Address
- Mikulaskovo Namesti 572/11, Stary Liskovec, 625 00 Brno, Czechia
Alergologie Nemcova s.r.o. - Respiratory Allergy and Asthma Research Center
Alergologie Nemcova s.r.o. is a specialized allergology research center dedicated to advancing the understanding and treatment of respiratory allergic conditions. The center demonstrates particular expertise in conducting clinical trials for patients with difficult-to-control asthma, focusing on novel therapeutic approaches that aim to improve disease management and patient outcomes.
- Uncontrolled asthma management and novel add-on therapies
- Evaluation of investigational compounds combined with maintenance ICS/LABA therapy
- Long-term efficacy and safety assessment in respiratory conditions
The research center's work emphasizes improving treatment outcomes for patients whose asthma remains uncontrolled despite medium-to-high dose inhaled corticosteroid and long-acting β2-agonist combination therapy. With a focus on evaluating innovative therapeutic agents like Tanimilast, Alergologie Nemcova s.r.o. contributes to the development of new treatment options aimed at reducing asthma exacerbation rates and enhancing quality of life for patients with challenging respiratory allergic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Alergologie Nemcova s.r.o.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tanimilast | 1 | Unknown | 2023-11-25 | 2023-11-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.